🏆 The #NeuroMadness Championship is here!
After weeks of polling, only one contender remains from each bracket:
#1 Natalizumab Vs. #2 OPERA 1 & 2 (MS)
One landmark therapy and one landmark clinical trial face off. Vote now to crown the champion‼️
#Neurology #MarchMadness #March
🚨 The votes are IN!🚨
The #NeuroMadness Championship matchup is officially set 🧠🏀
After weeks of fierce competition, only TWO teams remain:
#1 Natalizumab will take on #2 OPERA I & II (MS) in the #Finals
Stay tuned for the final poll of the tournament 👀
#Neurology #MarchMadness #March #Clinical
🚨 On to the #FinalFour in #NeuroMadness
Drug Classes:
#1 Natalizumab defeats #4 Gepants and will face #3 Anti-CGRP mAbs
Clinical Trials:
#6 SANAD (Epilepsy) upsets #1 AFFIRM (MS) and meets up with #2 OPERA I & II (MS)
Only 3 matchups remain so make sure to add your voice by voting! #Neurology
🏀 #NeuroMadness continues on our LinkedIn and X pages as the #Elite8 tips off!
Be sure to follow us on LinkeIn (@NeurologyLive) and X (@neurology_live) to participate
Let us know which drug class or clinical trial changed the field more by casting your vote now❗
#Neurology #MarchMadness #Neuro
🏀 #NeuroMadness Round 1 is finally complete!
Advancing in the Drug Classes bracket:
#1 Natalizumab - #2 S1P Modulators - #3 Anti-CGRP mAbs - #4 Gepants
Advancing in the Pivotal Trials bracket:
#1 AFFIRM - #2 OPERA I & II - #5 PROMISE-2 - #6 PALM
Stay tuned — the semifinal polls drop later today.
🏀 The first results of #NeuroMadness Round 1 are in
Drug Classes bracket:
#1 Natalizumab and #2 S1P Modulators advance
Pivotal Trials bracket:
The #1 AFFIRM trial and #2 Opera I & II trial move on
Be sure to follow along and cast your vote as
Neuro Madness continues❗
#Neurology #MarchMadness
🏀 The Madness is here 😠
Follow our socials to participate in #NeuroMadness, where you decide the most influential drugs and impactful trials over the past year 💊
Follow us on X (@Neurology_Live) and LinkedIn (@NeurologyLive) to help declare a winner.
It's March, anything can happen
#MarchMadness
